Ascletis Initiates Global Phase III for Oral Obesity Drug ASC30
Ascletis has initiated a global Phase III program for its oral small molecule GLP-1 drug candidate, ASC30, targeting obesity and overweight individuals. The program aims to enroll approximately 4,600 participants across two pivotal trials.
Ascletis has commenced a global Phase III program for ASC30, an oral small molecule drug candidate targeting the GLP-1 pathway for the treatment of obesity and overweight.
The large-scale trials will involve approximately 4,600 participants and are set to take place across the United States, Europe, and Canada.
In parallel, the company reported positive preclinical data for a first-in-class oral small molecule combination therapy. This investigational drug targets GLP-1, GIP, and amylin receptors and has shown promising results in non-human primate studies.